These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 29070117)

  • 1. [Efficacy Analysis of GEMOX Regimen for Treatment of Refractory Non-Hodgkin's Lymphoma].
    Yan SB; Chen ZG; Ma DL; Lyu X; Wang YL; Chen SB; Jie GT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1415-1419. PubMed ID: 29070117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
    Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and impact of GEMOX and GDP in the treatment of patients with non-Hodgkin's lymphoma.
    Zhang X; Wang B; Tao W; Si Y; Lin G; Zhang Y; Liu R; Yuan W
    J BUON; 2020; 25(2):1042-1049. PubMed ID: 32521904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety and efficacy evaluation of gemcitabine combined with oxaliplatin for the treatment of patients with lymphoma].
    Chen BL; Zhao Z; Qin SH; Liu L; Tan QL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):445-9. PubMed ID: 25948202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma].
    Yang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):84-8. PubMed ID: 26913399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
    Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP
    Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
    Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma].
    Hou Y; Wang HQ; Fu K; Liu XM; Zhang HL; Qian ZZ; Qiu LH; Li W; Zhou SY; Li LF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):306-10. PubMed ID: 22781046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
    Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Belayachi L; Bento L; García-Recio M; Sánchez JM; Villalonga P; Gutiérrez A; Fernández de Mattos S
    Br J Haematol; 2016 Sep; 174(6):899-910. PubMed ID: 27220900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
    Liu XM; Wang HQ; Zhang HL; Qiu LH; Li W; Li LF; Cui XZ; Liu PF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):779-82. PubMed ID: 19173813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
    Sym SJ; Lee DH; Kang HJ; Nam SH; Kim HY; Kim SJ; Eom HS; Kim WS; Suh C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):27-33. PubMed ID: 18839172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
    Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
    Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J; Merl M; Lee MX; Kaley K; Saif MW
    Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.